Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 24, 20 December 2023
Open
Access | Article
Icariin stimulates myeloid Leukemic cells differentiation by increasing smad4 protein abundance leading to the inhibition of myeloid Leukemic cell growth
* Author to whom correspondence should be addressed.
Abstract
As acute myeloid leukaemia (AML) is still a highly frequent disease (4.3 per 100,000 patients) worldwide and produces an incredibly high incidence rate (4 per 100,000), finding a more effective treatment or new direction of treatment is essential. This research aims to find a new direction of treatment by investigating cell differentiation. Focusing on the BMP signaling pathway, especially the protein of Smad4, the potential of increasing the chance of cell differentiation was found. Icariin (ICAR) was used to target the Smad4 pathway and hopefully become a potential treatment. Therefore, the hypothesis is set as the ICAR would increase the Smad4 level, which activates cell differentiation and potentially become a new treatment for AML. The experimental proposal was concluded in this research, and the combination of imaginary results was analyzed.
Keywords
AML, BMP Signaling Pathway, Differentiation
References
1. Shallis, R.M., et al. (2019) Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood reviews, 36: p. 70-87.
2. Bispo, J.A.B., P.S. Pinheiro, and E.K. Kobetz. (2020) Epidemiology and etiology of leukemia and lymphoma. Cold Spring Harbor perspectives in medicine, 10(6).
3. Chien, L.-N., et al. (2023) Epidemiology and survival outcomes of acute myeloid leukemia patients in Taiwan: A national population-based analysis from 2001 to 2015. Journal of the Formosan Medical Association, 122(6): p. 505-513.
4. Jaramillo, S. and R.F. Schlenk. (2023) Update on current treatments for adult acute myeloid leukemia: to treat acute myeloid leukemia intensively or non-intensively? That is the question. Haematologica, 108(2): p. 342-352.
5. Zhao, J.C., et al. (2022) A review of FLT3 inhibitors in acute myeloid leukemia. Blood reviews, 52: p. 100905.
6. Ishii, H. and S. Yano. (2022) New therapeutic strategies for adult acute myeloid leukemia. Cancers, 14(11): p. 2806.
7. Babakhanlou, R. and F. Ravandi-Kashani. (2023) Non-intensive acute myeloid leukemia therapies for older patients. Expert review of hematology, 16(3): p. 171-180.
8. Hanahan, D. (2022) Hallmarks of cancer: new dimensions. Cancer discovery, 12(1): p. 31-46.
9. Yang, L., et al. (2006) Acute myelogenous leukemia–derived SMAD4 mutations target the protein to ubiquitin‐proteasome degradation. Human mutation, 27(9): p. 897-905.
10. Imai, Y., et al. (2001) Mutations of the Smad4 gene in acute myelogeneous leukemia and their functional implications in leukemogenesis. Oncogene, 20(1): p. 88-96.
11. McCarthy, A.J. and R. Chetty, Smad4/DPC4. (2018) Journal of clinical pathology, 71(8): p. 661-664.
12. Chang, H., et al.(2000) Smad5 is essential for left–right asymmetry in mice. Developmental biology, 219(1): p. 71-78.
13. Pakravan, K., et al.(2022) SMAD4 contributes to chondrocyte and osteocyte development. Journal of Cellular and Molecular Medicine, 26(1): p. 1-15.
14. Seyedi, Z., et al. (2023) Icariin: A promising natural product in biomedicine and tissue engineering. Journal of Functional Biomaterials, 14(1): p. 44.
15. Xia, S.-l., et al.(2023) Icariin promotes the proliferation and osteogenic differentiation of bone-derived mesenchymal stem cells in patients with osteoporosis and T2DM by upregulating GLI-1. Journal of Orthopaedic Surgery and Research, 18(1): p. 500.
16. Xie, D., et al.(2023) Icariin promotes osteogenic differentiation by upregulating alpha-enolase expression. Biochemistry and Biophysics Reports, 34: p. 101471.
17. Zhang, X., et al. (2018) Local icariin application enhanced periodontal tissue regeneration and relieved local inflammation in a minipig model of periodontitis. International Journal of Oral Science, 10(2): p. 19.
18. Skopek, R., et al. (2023) Choosing the right cell line for acute myeloid leukemia (AML) research. International Journal of Molecular Sciences, 24(6): p. 5377.
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 3rd International Conference on Biological Engineering and Medical Science
- ISBN (Print)
- 978-1-83558-221-3
- ISBN (Online)
- 978-1-83558-222-0
- Published Date
- 20 December 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/24/20231090
- Copyright
- 20 December 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited